|
|
Post by saxcmann on Jun 2, 2016 18:52:35 GMT -5
Fidelity is 31.5% now. (6-2-16)
|
|
|
|
Post by saxcmann on May 31, 2016 18:58:14 GMT -5
Realistic numbers Patton.... 1 full time endo, supports afrezza. regular business hours, 30 mins visits, 4 days per week... 16 patients per day 12 diabetes 3 type-1 2 pass asthma, smoke, lung test 2 per day, best case. 1 realistic (current insulin in control) 1 x 4 days = 4 per week realistic. 2 x for high frequency providers. (See more patients per hour than above) 2500 full time endos, fyi. Best promotion, imo... Hire afrezza endo activists to speak with doctors. Sanofi never asked for afrezza only speakers and mnkd hasn't yet either. Last chance for mnkd management to get it right with 2nd launch. Mike C just might do it. Go mnkd! *hope the above helps board with real numbers to project and speculate with. Please help me with the numbers: 2 per day, best case. -> I do not understand how you get to 2. you said: 3 type-1 -> 3 out of 12 are T1, 9 are T2 ? Why do you differentiate between T1 and T2. Both are targets for Afrezza. 2 pass asthma, smoke, lung test -> 2 of 3 or 2 of 12 ? 1 realistic (current insulin in control) -> So 50% of all diabetics have their insulin not under control? Why would the endo only advice Afrezza to diabetics who are under control ? Isnt it one of the value proposals of Afrezza that patients comply better to the required insulin dosing? Sorry, yes some type-2s later in disease are targets. My guess is maybe one or two per day after initial treatments are tried. I was also trying to say some patients have their blood sugar levels under control so no need to change or try afrezza. I'd say more "freedom" with afrezza is true. Not sure percentage that comply. So you're right, adding 1 more possible patient to afrezza per day is about right for sales projections, imo. |
|
|
|
Post by saxcmann on May 31, 2016 9:51:47 GMT -5
Realistic numbers Patton....
1 full time endo, supports afrezza. regular business hours, 30 mins visits, 4 days per week...
16 patients per day
12 diabetes
3 type-1
2 pass asthma, smoke, lung test
2 per day, best case.
1 realistic (current insulin in control)
1 x 4 days = 4 per week realistic.
2 x for high frequency providers. (See more patients per hour than above)
2500 full time endos, fyi.
Best promotion, imo...
Hire afrezza endo activists to speak with doctors. Sanofi never asked for afrezza only speakers and mnkd hasn't yet either. Last chance for mnkd management to get it right with 2nd launch. Mike C just might do it. Go mnkd!
*hope the above helps board with real numbers to project and speculate with.
|
|
|
|
Post by saxcmann on May 23, 2016 9:39:39 GMT -5
Yes, I think scripts uptick is key for negotiations to advance quickly. Leverage will move towards mnkd for sure. I will post when first sales visit comes from mnkd afrezza rep. Hopefully June sometime. Sax- Are you a Dr? No. But know someone that is. |
|
|
|
Post by saxcmann on May 23, 2016 8:34:47 GMT -5
bthomas, problem with that scenario, is that, bottom line, we are not dealing from a position of strength and everyone knows it. I agree with that too. Interested companies called with two days of Sanofi canceling the agreement in January and here it is May 23rd. It is obvious, terms are difficult. If Mike C & Co. can somehow get scripts ramping up in short order with an exciting vibe, then that should bring some onlookers back out of the woodwork..... Yes, I think scripts uptick is key for negotiations to advance quickly. Leverage will move towards mnkd for sure. I will post when first sales visit comes from mnkd afrezza rep. Hopefully June sometime. |
|
|
|
Post by saxcmann on May 18, 2016 18:48:10 GMT -5
Fidelity down 51% to 45%
|
|
|
|
Post by saxcmann on May 12, 2016 12:09:49 GMT -5
Label change is still a long way away.... Why? Could be closer than you think... |
|
|
|
Post by saxcmann on May 11, 2016 14:56:56 GMT -5
Hey, not looking for advice. Just curious if others are having similar demons visiting them. My gut tells me to go to the well one more time (I usually listen to it). My heart tells me to hold and not be greedy (not so disciplined). Nearly 6 years, half a dozen buys and a couple sells and I'm as unsure today as I was in 2002. At this point I'm all in and (like most of you) seriously under water. But I can't seem to shake that little guy sitting on my shoulder. Ugh! I must say feeling the same way and similar history...by the way,I bought more today. |
|
|
|
Post by saxcmann on May 8, 2016 13:31:07 GMT -5
Fidelity is paying 53.75% interest to loan shares as of yesterday. Fidelity user as well: Are there a place where I can see this rate, or I will have to call their rep? Don't need to call. Go to website...account position then under loan securities. |
|
|
|
Post by saxcmann on May 5, 2016 11:11:11 GMT -5
Fidelity lends out shares to those shorting in the low 80% according to a Fidelity Rep I spoke with just a few minutes ago. Yes, what is your point? 2/3 to retail, 1/3 Fidelity.... |
|
|
|
Post by saxcmann on May 5, 2016 11:09:05 GMT -5
Fidelity is paying 53.75% interest to loan shares as of yesterday. At this rate I am going to start buying just as a trade to loan shares! Yes,it's considered especially someone like me who has already made the bet mnkd will succeed. |
|
|
|
Post by saxcmann on May 5, 2016 10:41:25 GMT -5
Fidelity is paying 53.75% interest to loan shares as of yesterday.
|
|
|
|
Post by saxcmann on Apr 21, 2016 21:40:09 GMT -5
No, I'd say just time starved and under a lot of pressure to see lots of patients and make zero mistakes. At any one time, they probably have 2 dozen reps who want a slice of their time to explain some new treatment they should try. They have to have some darn good motivation to spend the time to understand something that may or may not help them or their patients. Studies published in the NEJM make it easy for them to decide to spend some time. Screenshots from twitter - not so much. I'm sure Michael Castagna gets it and will address it appropriately, but it won't be easy or fast. I don't post much but felt compelled here... Mnkdnut is 100% correct with his thread comments. Doctors need scientific results from studies not blog reports. Peppy...yes, doctors are stubborn as hell too! |
|
|
|
Post by saxcmann on Apr 11, 2016 19:37:51 GMT -5
Couple questions.... Do shareholders who are lending shares to shorts need to pull them back to vote them? The proxy states that non voted shares are counted as NO votes. Isn't it normally the other way around? Non voted shares go with the bod? I'm sure they're non issues, between Manns shares and the inst who are on board they've got 50% covered. Two good questions. The answer to the first one is that voting rights belong to the registered holder, not the borrower. You do not need to pull back your shares to vote them.
The second question is a very important one, and it a matter of state corporate law. Most states word their law on share increases such that it requires an affirmative vote of the majority of all shares outstanding, while most corporate issues are decided by a majority of the shares that cast a vote. You see the difference? Most corporate actions have no requirement on the number of shares that actually vote, while increasing the authorized shares must have a certain number of actually cast "yes" votes. Brokers can give their proxies to management on many routine corporate votes (like confirmation of the auditing firm), but the exchanges and the SEC do not allow brokers to vote on non-routine matters, and an increase in authorized shares is a non-routine matter. Since shares that are never voted are still part of the total outstanding shares they have the same effect as a "no" vote in this case.
The brokers must forward the proxy and voting materials to the beneficial owner of the shares, and the beneficial owner must cast the vote. If your shares are in street name, your broker will be sending you the necessary paperwork. Foreign brokers, like those who deal with TASE traded shares, are under no legal obligation to forward the materials although many of them do. A lot of companies find that they cannot raise capital because they cannot collect the required number of "yes" votes simply because too many small shareholders throw the voting materials in the trash without acting on them. As you noted, the shares held by the Mann trusts are probably reliable votes, but the institutions cannot be relied upon since only beneficial owners can vote. In some cases the institution is an actively managed mutual fund that actually owns the shares, but in other cases the institution is a conduit to the beneficial owner and must forward the proxies.
If you agree with the proposal and you hold your shares in street name, be sure to vote when you get the proxy.
And how do you recommend we vote Matt, with info we have right now? I'm assuming we'll have more info (from other matt) by the time we vote?... |
|
|
|
Post by saxcmann on Mar 31, 2016 8:37:52 GMT -5
For those of you who do not receive the "Insulin News" email from Sanofi, I had a nice email in my inbox this morning. "Hi Scott, As you may have seen in public media communications, Afrezza® will be transferred back from Sanofi to MannKind Corporation on April 4, 2016. Future communications to you on Afrezza may come from MannKind Corporation. In addition, you may continue to receive diabetes and other health related communications from Sanofi. From April 5, 2016 onwards all questions regarding Afrezza should be directed to MannKind Corporation at 1-877-323-8505 or you can visit www.Afrezza.com." So we are on track for the timeline to return Afrezza. For now, cash is king. Matt did not sound concerned during the last call. Hopefully Matt can share some good news shortly. Pfizer gave Nectar $135mm when they discontinued Exubera. I don't believe Sanofi won't pay that kind of money to Mannkind but time will tell. Matt also stated they were happy with Sanofi while all along he knew things were going to unravel. Taking a CEOs word can be a very dangerous thing to an investor. It is more important that this failing company SHOWS us rather than tells us as it has very little success in proving it can execute successfully. And I apologize in advance to those who get emotionally hurt by straight forward facts. Straight forward facts??!....lol |
|
